Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Tarceva erlotinib: Phase III data

In the double-blind, placebo-controlled Phase III AVITA trial (BO17706) in 607 patients with metastatic pancreatic

Read the full 158 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE